Form 13-F position report

ENANTA PHARMACEUTICALS INC

Reported by Invesco Ltd

ENTA CUSIP 29251M106 Manager CIK 0000914208

Reported 342,007 shares, up 52,163 (18.0%) from the prior quarter.

Reported value 12.3%; share count 18.0% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q1 2022
Shares 342,007 Quarter-end amount reported
Reported value $24,343,000 Fair value at quarter end
Consecutive quarters held 33 Through Q1 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 6032000
2021-12-31 21674000
2022-03-31 24343000
2022-06-30 23613000
2022-09-30 18474000
2022-12-31 4958987
2023-03-31 12203579
2023-06-30 1800233
2023-09-30 207382
2023-12-31 190383
2024-03-31 759492
2024-06-30 562432
2024-09-30 449914
2024-12-31 268031
2025-03-31 332730
2025-06-30 475403
2025-09-30 714585
2025-12-31 4002599
2026-03-31 2298685
2026-06-30 867948

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for ENANTA PHARMACEUTICALS INC held by Invesco Ltd.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 59,530 -122,472 (-67.3%) < 0.01% $867,948 2026-08-14
Q1 2026 Reduced 182,002 -71,809 (-28.3%) < 0.01% $2,298,685 2026-05-12
Q4 2025 Added 253,811 +194,113 (325.2%) < 0.01% $4,002,599 2026-02-19
Q3 2025 Reduced 59,698 -3,186 (-5.1%) < 0.01% $714,585 2025-11-13
Q2 2025 Added 62,884 +2,607 (4.3%) < 0.01% $475,403 2025-08-13
Q1 2025 Added 60,277 +13,663 (29.3%) < 0.01% $332,730 2025-05-12
Q4 2024 Added 46,614 +3,186 (7.3%) < 0.01% $268,031 2025-02-13
Q3 2024 Added 43,428 +64 (0.1%) < 0.01% $449,914 2024-11-12
Q2 2024 Reduced 43,364 -135 (-0.3%) < 0.01% $562,432 2024-08-13
Q1 2024 Added 43,499 +23,267 (115.0%) < 0.01% $759,492 2024-05-14
Q4 2023 Added 20,232 +1,666 (9.0%) < 0.01% $190,383 2024-02-13
Q3 2023 Reduced 18,566 -65,557 (-77.9%) < 0.01% $207,382 2023-11-13
Q2 2023 Reduced 84,123 -217,647 (-72.1%) < 0.01% $1,800,233 2023-08-11
Q1 2023 Added 301,770 +195,171 (183.1%) < 0.01% $12,203,579 2023-05-12
Q4 2022 Reduced 106,599 -249,578 (-70.1%) < 0.01% $4,958,987 2023-02-13
Q3 2022 Reduced 356,177 -143,353 (-28.7%) < 0.01% $18,474,000 2022-11-14
Q2 2022 Added 499,530 +157,523 (46.1%) < 0.01% $23,613,000 2022-08-15
Q1 2022 Added 342,007 +52,163 (18.0%) < 0.01% $24,343,000 2022-05-16
Q4 2021 Added 289,844 +183,676 (173.0%) < 0.01% $21,674,000 2022-02-14
Q3 2021 Reduced 106,168 -174,996 (-62.2%) < 0.01% $6,032,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

196 managers reported ENANTA PHARMACEUTICALS INC for Q1 2022.

Managers reporting ENANTA PHARMACEUTICALS INC in Q1 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 3,516,606 +45,191 < 0.01% $250,312,000 32 qtrs
VANGUARD GROUP INC Reduced 1,589,224 -36,685 < 0.01% $113,122,000 36 qtrs
FARALLON CAPITAL MANAGEMENT LLC Reduced 1,550,000 -23,829 0.53% $110,329,000 19 qtrs
STATE STREET CORPORATION Added 1,308,586 +181,517 < 0.01% $93,145,000 35 qtrs
ARMISTICE CAPITAL LLC Added 1,124,000 +68,000 1.55% $80,006,000 24 qtrs
RA CAPITAL MANAGEMENT L P New 964,212 +964,212 1.5% $68,633,000 1 qtr
NORTHERN TRUST CORPORATION Reduced 928,093 -84,071 0.01% $66,061,000 36 qtrs
FIRST MANHATTAN CO Reduced 789,311 -180,425 0.18% $56,183,000 23 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 607,100 -107,300 0.05% $43,213,000 25 qtrs
DIMENSIONAL FUND ADVISORS LP Reduced 593,520 -8,218 0.01% $42,244,000 29 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2022
Filed
May 16, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
333,611
None
8,396

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.